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Table 2. Clinical features of organizing pneumonia (OP) in RA patients 
 
Demographics  Clinical features of OP  (n=24) 
Number 24* Symptoms & Lab. data  
Male/Female 9/15   Respiratory symptoms 64%  
Smoking history 9* (Current smoker; 2)     cough 42% 
Age of RA onset 49.6±12.6**     dyspnea 29% 
RF  positivity (titers) 67% (168±378(U/ml))      sputum 17% 
Anti-CCP Ab 82% (14/17)*** Fever 79% 
Pre-existing lung disease 6*  
(ILD; 2, BE; 2,  
COPD; 1, 
bronchiolitis 1,  
Cystic lesions 1) 
CRP levels (mg/dl) 10.66±7.87 
Cases with CRP>1mg/dl 88% 
Exacerbation of arthritis 11%  (2/18) 
New onset or  
exacerbation of arthritis  
21% 
(New onset; 3* , 
exacerbation; 2 ) 
Age of OP onset  60.4± 9.6  Imaging (n=24) 
Interval from the onset of 
RA to OP (year) 
10.8± 11.9 
(range; -4 to +34 ) 
Bilateral lung lesions 37.5% 
OP onset pattern OP > RA; 3* Multiple lesions 75% 
OP=RA; 3* Consolidation 100% 
RA > OP; 18*  Ground glass opacities 37.5%  
RA status just before the onset of OP  (n=18) Reticular opacities 8% 
Disease Activity High; 4* Pleural effusion 13% 
Moderate; 4* Spontaneous dis- 
appearance of infiltration 
33% 
Low; 8* 
Clinical remission; 2* Response to Treatment  (n=24) 
CRP levels (mg/dl) 2.86±5.2**    Antibiotics† 8%   (1/13) 
Cases with CRP>1mg/dl 17%  (3/18)    Glucocorticoid 100% (16/16) 
Medication for RA at the onset of OP  (n=18) Outcomes (n=24) 
Biologics 8 * Observation period (year) 6.7±3.5 
  MTX 14* Relapse 21%  
Other DMARDs 4*    Duration to relapse 3mo-14 years 
Median; 1.7 year 
  Glucocorticoid 13*   Death 13 % 
*; number of cases, **; mean± standard deviation , *** ;number of cases positive for 
events/ number of cases examined, † ;partial response. BE; bronchoectasia, COPD; 
Chronic Obstructive Pulmonary Disease, DMARD; Disease-modifying anti-rheumatic 
drugs  ILD; interstitial lung disease, MTX; Methotrexate. 
 
 
 
 
